CORD-19:775b90287b44353bee979abb0970a4666022f86d / 781170-781321 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/775b90287b44353bee979abb0970a4666022f86d","sourcedb":"CORD-19","sourceid":"775b90287b44353bee979abb0970a4666022f86d","text":"Patients treated with AZ/FP achieved at least a 50% reduction in rTOSS significantly sooner than patients treated with FP (P=.02) or placebo (P≤.0001).","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T78857","span":{"begin":0,"end":151},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T78857","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T25","span":{"begin":0,"end":151},"obj":"Sentence"}],"attributes":[{"subj":"T25","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93ece2","default":true},{"id":"CORD-19_Custom_license_subset","color":"#ecc893"}]}]}}